Global Preimplantation Genetic Screening (PGS) Technology Market, By Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Services (Reagents and Consumables, Instruments, Software and Services), End User (Maternity Centers and Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories and Academic Institutes), Test Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other PGT Types), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease, Others) – Industry Trends and Forecast to 2029
Preimplantation Genetic Screening (PGS) Technology Market Analysis and Size
The size of the global market for preimplantation genetic screening (PGS) technology is anticipated to grow at a CAGR of 10.50% during the forecast period. Recent technological developments have significantly altered the practice of prenatal screening and early diagnosis of chromosomal abnormalities in an embryo. Successful in vitro fertilisation (IVF) processing has been achieved by expanding non-invasive cell-free foetal DNA-based detection procedures as well as carrier screening panels into prenatal care. Preimplantation genetic screening (PGS) technology is a market-driver due to the early detection of congenital disorders in the beginning phases of the IVF workflow, gradually reducing the chance of inherited chromosomal abnormalities in foetuses.
Data Bridge Market Research analyses that the preimplantation genetic screening (PGS) technology market which was USD 552.50 million in 2021, would rocket up to USD 1228.09 million by 2029, and is expected to undergo a CAGR of 10.50% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Preimplantation Genetic Screening (PGS) Technology Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Procedure Type (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Services (Reagents and Consumables, Instruments, Software and Services), End User (Maternity Centers and Fertility Clinics, Hospitals, Diagnostic Labs, and Service Providers, Research Laboratories and Academic Institutes), Test Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other PGT Types), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Beijing Genomics Institute (BGI) (China), Abbott (U.S.), Siemens (Germany), QIAGEN (Germany)
|
|
Market Opportunities
|
|
Market Definition
Preimplantation genetic screening (PGS), also known as PGTa (preimplantation testing for aneuploidy), is a specialised, cutting-edge diagnostic procedure used to ascertain the chromosomal status of embryos at a very early stage of embryo development. It is an additional or "add-on" to standard IVF/ICSI therapy.
Preimplantation Genetic Screening (PGS) Technology Market Dynamics
Drivers
- Rising number of fertility clinics
In the forecast period of 2022–2029, factors such as the rising number of fertility clinics around the world, the prevalence of funds from government and private organisations for preimplantation genetic screening, the declining rate of fertility, the adoption of cutting-edge technology, and the rising risk of chromosomal abnormalities with increasing maternal age are likely to boost the growth of the preimplantation genetic screening (PGS) technology market.
- Increase in healthcare infrastructure
The preimplantation genetic screening (PGS) technology market will expand throughout the forecast period due to the prevalence of an enhanced healthcare infrastructure and an increase in tourist activities.
Opportunities
The growth of the preimplantation genetic screening (PGS) technology market is fuelled by the prevalence of funds from government and private organisations for preimplantation genetic screening, the declining fertility rate, and the adoption of cutting-edge technology. This will provide beneficial opportunities for the market growth.
Restraints/Challenges
- High cost
On the other hand, the stringent government regulations and the high procedure cost will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the preimplantation genetic screening (PGS) technology market.
This preimplantation genetic screening (PGS) technology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the preimplantation genetic screening (PGS) technology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Preimplantation Genetic Screening (PGS) Technology Market Scope
The preimplantation genetic screening (PGS) technology market is segmented on the basis of procedure type, technology, product & services, test type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Procedure Type
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
Technology
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Fluorescence in Situ Hybridization
- Comparative Genomic Hybridization
- Single-Nucleotide Polymorphism
Product and Services
- Reagents and Consumables
- Instruments
- Software and Services
End User
- Maternity Centers
- Fertility Clinics
- Hospitals, Diagnostic Labs
- Service Providers
- Research Laboratories
- Academic Institutes
Test Type
- Chromosomal Abnormalities
- X-linked Diseases, Embryo Testing
- Aneuploidy Screening
- HLA Typing
- Other PGT Types
Application
- Embryo HLA Typing for Stem Cell Therapy
- IVF Prognosis
- Late Onset Genetic Disorders
- Inherited Genetic Disease
- Others
Preimplantation Genetic Screening (PGS) Technology Market Regional Analysis/Insights
The preimplantation genetic screening (PGS) technology market is analysed and market size insights and trends are provided by country, procedure type, technology, product & services, test type, application and end user as referenced above.
The countries covered in the preimplantation genetic screening (PGS) technology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the preimplantation genetic screening (PGS) technology market due to the growing number of late pregnancies along with rising adoption of IVF procedures.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing number of advancements and adoption of PGT workflows.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Preimplantation Genetic Screening (PGS) Technology Market Share Analysis
The preimplantation genetic screening (PGS) technology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to preimplantation genetic screening (PGS) technology market.
Some of the major players operating in the preimplantation genetic screening (PGS) technology market are:
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- PerkinElmer, Inc. (U.S.)
- CooperSurgical, Inc. (U.S.)
- Beijing Genomics Institute (BGI) (China)
- Abbott (U.S.)
- Siemens (Germany)
- QIAGEN (Germany)
SKU-